New York City Chapter Meeting
Co-hosted with MIT Enterprise Forum
DATE & TIME
Thursday, June 7, 2012
5:30 PM - 8:00 PM
LOCATION
K&L Gates LLP
599 Lexington Avenue (53rd Street) - 32nd Floor
New York, NY 10022
TOPIC
The Age of "Big Data" in Bioscience is Here, But are We Prepared for it?
DESCRIPTION
The bioscience research community is producing more and larger sets of data in its quest to understand biology and manage disease. Much of these data are being generated by teams of scientists spanning many institutions and geographies. As we come to appreciate these data as a new asset class, we need to understand how to properly manage, protect and share this asset so its value can be realized.
A distinguished panel of experts will discuss managing and protecting “Big data” as i) intellectual property, ii) trade secrets and iii) open source. We will explore opportunities and challenges including storage and access issues, data protection, ownership (who owns the “$1,000 genome” data – the producer or the purchaser?) and future advances in analysis and utility.
Moderator
Eric Vieira, Ph.D.
Assistant Director, Office of Technology and Business Development
Mount Sinai School of Medicine
PANEL
Louis C. Cullman, Esq.
Partner
K&L Gates, LLP
Primary Outside IP Counsel to the Bill and Melinda Gates
Foundation's Global Health Program
Brett J. Davis,
Senior Director
Oracle Health Sciences
David Greenwald, Ph.D.,
Co-founder & Managing Director
Relay Technology Management, Inc.
REGISTRATION
LES Member: $30
Non-Member: $40
Onsite
LES Member: $50
Non-Member: $60
Online Registration Deadline: Tuesday, June 5, 12 PM ET
Onsite Registration Available
CANCELLATION POLICY
No refunds after June 5
Substitutions are permitted
SPEAKER BIOS
Eric Vieira - Assistant Director for the Mount Sinai School of Medicine's Office of Technology and Business Development, where he is building innovative programs to foster entrepreneurship and technology commercialization. Prior to joining Mount Sinai, Eric was the Senior Biotech & Pharma Analyst at Majestic Research, an independent equity research firm. Earlier in his career, Eric was an Associate Biotech Analyst with Rodman & Renshaw, and then Lazard Capital Markets as a Specialty Biotech Analyst.
Eric is also a co-director and lecturer for the New York State Center for Biotechnology's Fundamentals of the Bioscience Industry program.
Eric has a Ph.D. in Developmental Genetics from New York University's School of Medicine and a B.A in molecular biology & biochemistry from Rutgers College, Rutgers University.
Louis C. Cullman - Partner in the Orange County office of K&L Gates LLP specializing in intellectual property (IP) law where he manages the transactional IP group. Louis also specializes in the unique IP issues associated with large not-for-profit organizations including the New York Blood Center and the Bill and Melinda Gates Foundation (BMGF).
As Primary Outside IP Counsel to the BMGF Global Health Program, Louis has helped create policies and procedures (including Global Access Polices) designed to facilitate data, information and material sharing between members of multi-national consortiums comprised of academia and industry.
Prior to attending law school Louis served as a clinical laboratory director, is a licensed Clinical Microbiologist, and has extensive technical experience in the design and manufacturing of in vitro diagnostic devices.
Brett J. Davis – Senior Director in Oracle's Health Sciences Global Business Unit. In this role, Brett is responsible for helping shape Oracle's healthcare analytics and personalized medicine strategy and solutions. He works closely with leaders in healthcare and life sciences to help leverage innovative information technologies and applications to innovate and grow.
Brett also serves on the External Advisory Board for the
University of Pennsylvania Department of Medical Ethics and Health Policy and co-chairs the NY State PACeR Business Model workgroup. Previously Brett served on the Board of
Directors of the Personalized Medicine Coalition, and participated on the US Department of Health and Human Services HRSA Genetic Services Policy Project Advisory Panel.
Prior to joining Oracle, Brett was a Business Unit Executive in IBM's Healthcare and Life Sciences business and led business development and marketing efforts at several venture backed bioinformatics firms.
Brett is a graduate of Pennsylvania State University where he was enrolled in the accelerated Science BS/MBA Program, and graduated as the Eberly College of Science Student Marshall.
David Greenwald - Co-founder of Relay Technology Management, and currently its Managing Director. Previously, David was an Associate Investigator at the Naval Medical Research Center in Silver Spring, MD and worked with the Food and Drug Administration on 510(k) applications for diagnostic devices for dengue fever.
Dr. Greenwald was a Howard Hughes Medical Institute (HHMI) research fellow while earning a B.S. in Cellular Biology and Molecular Genetics from the University of Maryland. He was awarded an NIH Ruth L. Kirschstein National Research Service Award (NRSA) towards his Ph.D. research dissertation on gene therapy for Retinitis Pigmentosa.